Abstract
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder with progressive loss of memory and other cognitive functions. The pathogenesis of this disease is complex and multifactorial, and remains obscure until now. To enhance the declined level of acetylcholine (ACh) resulting from loss of cholinergic neurons, acetylcholinesterase (AChE) inhibitors are developed and successfully approved for AD treatment in the clinic, with a limited therapeutic effectiveness. At present, it is generally accepted that multi-target strategy is potently useful for designing novel drugs for AD. Accumulated evidence reveals that Kv channels, which are broadly expressed in brain and possess crucial functions in modulating the neuronal activity, are inhibited by several acetylcholinesterase (AChE) inhibitors, such as tacrine, bis(7)-tacrine, donepezil and galantamine. Inhibition of Kv channels by these AChE inhibitors can generate neuroprotective effects by either mitigating Aβ toxicity and neuronal apoptosis, or facilitating cell proliferation. These inhibitory effects provide additional explanations for clinical beneficial effectiveness of AChE inhibitors, meaning that Kv channel is a promising candidate target for novel drugs for AD therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
References
Avila J, Lucas JJ, Perez M, Hernandez F (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84(2):361–384. https://doi.org/10.1152/physrev.00024.2003
Bauer CK, Schwarz JR (2018) Ether-à-go-go K(+) channels: effective modulators of neuronal excitability. J Physiol 596(5):769–783. https://doi.org/10.1113/jp275477
Birks JS, Chong LY, Grimley Evans J (2015) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 9(9):CD001191. https://doi.org/10.1002/14651858.CD001191.pub4
Birnbaum SG, Varga AW, Yuan LL, Anderson AE, Sweatt JD, Schrader LA (2004) Structure and function of Kv4-family transient potassium channels. Physiol Rev 84(3):803–833. https://doi.org/10.1152/physrev.00039.2003
Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED (2007) The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 104(27):11418–11423. https://doi.org/10.1073/pnas.0610467104
Bougis PE, Martin-Eauclaire MF (2015) Shal-type (Kv4.x) potassium channel pore blockers from scorpion venoms. Sheng Li Xue Bao 67(3):248–254
Campolongo P, Ratano P, Ciotti MT, Florenzano F, Nori SL, Marolda R, Palmery M, Rinaldi AM, Zona C, Possenti R, Calissano P, Severini C (2013) Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of Kv potassium channels. PLoS One 8(11):e78036. https://doi.org/10.1371/journal.pone.0078036
Chae YJ, Lee HJ, Jeon JH, Kim IB, Choi JS, Sung KW, Hahn SJ (2015) Effects of donepezil on hERG potassium channels. Brain Res 1597:77–85. https://doi.org/10.1016/j.brainres.2014.11.057
Cheng DH, Ren H, Tang XC (1996) Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 8(1):97–101. https://doi.org/10.1097/00001756-199612200-00020
Cotella D, Hernandez-Enriquez B, Wu X, Li R, Pan Z, Leveille J, Link CD, Oddo S, Sesti F (2012) Toxic role of K+ channel oxidation in mammalian brain. J Neurosci 32(12):4133–4144. https://doi.org/10.1523/jneurosci.6153-11.2012
Dallas ML, Boyle JP, Milligan CJ, Sayer R, Kerrigan TL, McKinstry C, Lu P, Mankouri J, Harris M, Scragg JL, Pearson HA, Peers C (2011) Carbon monoxide protects against oxidant-induced apoptosis via inhibition of Kv2.1. FASEB J 25(5):1519–1530. https://doi.org/10.1096/fj.10-173450
de Jong IEM, Jepps TA (2018) Impaired Kv7 channel function in cerebral arteries of a tauopathy mouse model (rTg4510). Physiol Rep 6 (23):e13920. https://doi.org/10.14814/phy2.13920
Devanand DP (2014) Whatever happened to new treatments for Alzheimer's disease? J Clin Psychiatry 75(7):775–776. https://doi.org/10.4088/JCP.14ac09246
Feinshreiber L, Singer-Lahat D, Friedrich R, Matti U, Sheinin A, Yizhar O, Nachman R, Chikvashvili D, Rettig J, Ashery U, Lotan I (2010) Non-conducting function of the Kv2.1 channel enables it to recruit vesicles for release in neuroendocrine and nerve cells. J Cell Sci 123(Pt 11):1940–1947. https://doi.org/10.1242/jcs.063719
He Y, Fang X, Shi J, Li X, Xie M, Liu X (2020) Apigenin attenuates pulmonary hypertension by inducing mitochondria-dependent apoptosis of PASMCs via inhibiting the hypoxia inducible factor 1α-KV1.5 channel pathway. Chem Biol Interact 317:108942. https://doi.org/10.1016/j.cbi.2020.108942
Hu CL, Zeng XM, Zhou MH, Shi YT, Cao H, Mei YA (2008) Kv 1.1 is associated with neuronal apoptosis and modulated by protein kinase C in the rat cerebellar granule cell. J Neurochem 106(3):1125–1137. https://doi.org/10.1111/j.1471-4159.2008.05449.x
Hu D, Liu J, Xiong H (2009) Enhancement of neuronal outward delayed rectifier K+ current by human monocyte-derived macrophages. Glia 57(14):1492–1500. https://doi.org/10.1002/glia.20865
Hu XM, Ren S, Li K, Li XT (2020) Tacrine modulates Kv2.1 channel gene expression and cell proliferation. Int J Neurosci 130(8):781–787. https://doi.org/10.1080/00207454.2019.1705811
Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7(8):656–664. https://doi.org/10.2174/156720510793611592
Jan LY, Jan YN (2012) Voltage-gated potassium channels and the diversity of electrical signalling. J Physiol 590(11):2591–2599. https://doi.org/10.1113/jphysiol.2011.224212
Johnston J, Forsythe ID, Kopp-Scheinpflug C (2010) Going native: voltage-gated potassium channels controlling neuronal excitability. J Physiol 588(Pt 17):3187–3200. https://doi.org/10.1113/jphysiol.2010.191973
Kerrigan TL, Atkinson L, Peers C, Pearson HA (2008) Modulation of 'A'-type K+ current by rodent and human forms of amyloid beta protein. Neuroreport 19(8):839–843. https://doi.org/10.1097/WNR.0b013e3282ff636b
Kojima J, Onodera K (1998) Effects of NIK-247 and tacrine on muscarinic receptor subtypes in rats. Gen Pharmacol 30(4):537–541. https://doi.org/10.1016/s0306-3623(97)00303-0
Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (2000) Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur J Pharmacol 389(2-3):173–179. https://doi.org/10.1016/s0014-2999(99)00876-6
Kumar A, Gupta V, Sharma S (2021) Donepezil. 2021/05/07 edn. StatPearls Publishing LLC, Treasure Island (FL)
Li XY, Zhang J, Dai JP, Liu XM, Li ZW (2010) Actions of bis(7)-tacrine and tacrine on transient potassium current in rat DRG neurons and potassium current mediated by K(V)4.2 expressed in Xenopus oocyte. Brain Res 1318:23–32. https://doi.org/10.1016/j.brainres.2009.12.047
Li Y, Hu GY (2002a) Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons. Neurosci Lett 329(2):153–156. https://doi.org/10.1016/s0304-3940(02)00620-1
Li Y, Hu GY (2002b) Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons. Neurosci Lett 324(1):25–28. https://doi.org/10.1016/s0304-3940(02)00167-2
Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain 141(2):596–612. https://doi.org/10.1093/brain/awx346
Mahdavi M, Hariri R, Mirfazli SS, Lotfian H, Rastergari A, Firuzi O, Edraki N, Larijani B, Akbarzadeh T, Saeedi M (2019) Synthesis and Biological Activity of Some Benzochromenoquinolinones: Tacrine Analogs as Potent Anti-Alzheimer's Agents. Chem Biodivers 16(4):e1800488. https://doi.org/10.1002/cbdv.201800488
Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23(1):134–147. https://doi.org/10.1016/s0891-5849(96)00629-6
Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430(7000):631–639. https://doi.org/10.1038/nature02621
Mezeiova E, Chalupova K, Nepovimova E, Gorecki L, Prchal L, Malinak D, Kuca K, Soukup O, Korabecny J (2019) Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease. Curr Alzheimer Res 16(9):772–800. https://doi.org/10.2174/1567205016666190228122956
Moudgil R, Michelakis ED, Archer SL (2006) The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 13(8):615–632. https://doi.org/10.1080/10739680600930222
Murakoshi H, Trimmer JS (1999) Identification of the Kv2.1 K+ channel as a major component of the delayed rectifier K+ current in rat hippocampal neurons. J Neurosci 19(5):1728–1735
Nerbonne JM, Nichols CG, Schwarz TL, Escande D (2001) Genetic manipulation of cardiac K(+) channel function in mice: what have we learned, and where do we go from here? Circ Res 89(11):944–956
Nie H, Yu WJ, Li XY, Yuan CH, Pang YP, Li CY, Han YF, Li ZW (2007) Inhibition by bis(7)-tacrine of native delayed rectifier and KV1.2 encoded potassium channels. Neurosci Lett 412(2):108–113. https://doi.org/10.1016/j.neulet.2006.10.047
Oset-Gasque MJ, Marco-Contelles JL (2020) Tacrine-Natural-Product Hybrids for Alzheimer's Disease Therapy. Curr Med Chem 27(26):4392–4400. https://doi.org/10.2174/0929867325666180403151725
Pan Y, Xu X, Tong X, Wang X (2004) Messenger RNA and protein expression analysis of voltage-gated potassium channels in the brain of Abeta(25-35)-treated rats. J Neurosci Res 77(1):94–99. https://doi.org/10.1002/jnr.20134
Pan Y, Xu X, Wang X (2003a) Rivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons. Br J Pharmacol 140(5):907–912. https://doi.org/10.1038/sj.bjp.0705503
Pan YP, Xu XH, Wang XL (2003b) Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons. Neurosci Lett 336(1):37–40. https://doi.org/10.1016/s0304-3940(02)01235-1
Pannaccione A, Boscia F, Scorziello A, Adornetto A, Castaldo P, Sirabella R, Taglialatela M, Di Renzo GF, Annunziato L (2007) Up-regulation and increased activity of KV3.4 channels and their accessory subunit MinK-related peptide 2 induced by amyloid peptide are involved in apoptotic neuronal death. Mol Pharmacol 72(3):665–673. https://doi.org/10.1124/mol.107.034868
Pieri M, Amadoro G, Carunchio I, Ciotti MT, Quaresima S, Florenzano F, Calissano P, Possenti R, Zona C, Severini C (2010) SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology 58(1):268–276. https://doi.org/10.1016/j.neuropharm.2009.06.029
Plant LD, Webster NJ, Boyle JP, Ramsden M, Freir DB, Peers C, Pearson HA (2006) Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ current. Neurobiol Aging 27(11):1673–1683. https://doi.org/10.1016/j.neurobiolaging.2005.09.038
Ravens U, Wettwer E (2011) Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc Res 89(4):776–785. https://doi.org/10.1093/cvr/cvq398
Rogawski MA (1987) Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons. Eur J Pharmacol 142(1):169–172. https://doi.org/10.1016/0014-2999(87)90670-4
Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158(9):1021–1031
Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545–584. https://doi.org/10.1146/annurev.pharmtox.43.100901.140248
Singer-Lahat D, Chikvashvili D, Lotan I (2008) Direct interaction of endogenous Kv channels with syntaxin enhances exocytosis by neuroendocrine cells. PLoS One 3(1):e1381. https://doi.org/10.1371/journal.pone.0001381
Solntseva EI, Bukanova JV, Skrebitsky VG (2013) Donepezil in low micromolar concentrations modulates voltage-gated potassium currents in pyramidal neurons of rat hippocampus. Biochem Biophys Res Commun 430(3):1066–1071. https://doi.org/10.1016/j.bbrc.2012.12.037
Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y (2000) Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 7(3):303–339. https://doi.org/10.2174/0929867003375191
Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306(2):772–777. https://doi.org/10.1124/jpet.103.050104
Takaya T, Okamoto M, Yodoi K, Hata K, Kijima Y, Nakajima H, Nishikawa Y, Kita T, Ito M, Seo T, Kawashima S (2009) Torsades de Pointes with QT prolongation related to donepezil use. J Cardiol 54(3):507–511. https://doi.org/10.1016/j.jjcc.2009.03.011
Tanaka A, Koga S, Hiramatsu Y (2009) Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Intern Med 48(14):1219–1223
Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821–827. https://doi.org/10.1124/jpet.102.041616
Tun MK, Herzon SB (2012) The pharmacology and therapeutic potential of (-)-huperzine A. J Exp Pharmacol 4:113–123. https://doi.org/10.2147/jep.s27084
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271(13):992–998
Wilkinson DG (1999) The pharmacology of donepezil: a new treatment of Alzheimer's disease. Expert Opin Pharmacother 1(1):121–135. https://doi.org/10.1517/14656566.1.1.121
Wu DC, Xiao XQ, Ng AK, Chen PM, Chung W, Lee NT, Carlier PR, Pang YP, Yu AC, Han YF (2000) Protection against ischemic injury in primary cultured mouse astrocytes by bis(7)-tacrine, a novel acetylcholinesterase inhibitor [corrected]. Neurosci Lett 288(2):95–98. https://doi.org/10.1016/s0304-3940(00)01198-8
Wu X, Hernandez-Enriquez B, Banas M, Xu R, Sesti F (2013) Molecular mechanisms underlying the apoptotic effect of KCNB1 K+ channel oxidation. J Biol Chem 288(6):4128–4134. https://doi.org/10.1074/jbc.M112.440933
Xiao XQ, Lee NT, Carlier PR, Pang Y, Han YF (2000) Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine. Neurosci Lett 290(3):197–200. https://doi.org/10.1016/s0304-3940(00)01357-4
Yang CT, Lu GL, Hsu SF, MacDonald I, Chiou LC, Hung SY, Chen YH (2018) Paeonol promotes hippocampal synaptic transmission: The role of the Kv2.1 potassium channel. Eur J Pharmacol 827:227–237. https://doi.org/10.1016/j.ejphar.2018.03.020
Yanovsky I, Finkin-Groner E, Zaikin A, Lerman L, Shalom H, Zeeli S, Weill T, Ginsburg I, Nudelman A, Weinstock M (2012) Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. J Med Chem 55(23):10700–10715. https://doi.org/10.1021/jm301411g
Yuan H, Wang WP, Feng N, Wang L, Wang XL (2011) Donepezil attenuated oxygen-glucose deprivation insult by blocking Kv2.1 potassium channels. Eur J Pharmacol 657(1-3):76–83. https://doi.org/10.1016/j.ejphar.2011.01.054
Zagórska A, Jaromin A (2020) Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy. Molecules 25(15). https://doi.org/10.3390/molecules25153337
Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G (2002) Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82(14):941–944
Zhong CB, Pan YP, Tong XY, Xu XH, Wang XL (2005) Delayed rectifier potassium currents and Kv2.1 mRNA increase in hippocampal neurons of scopolamine-induced memory-deficient rats. Neurosci Lett 373(2):99–104. https://doi.org/10.1016/j.neulet.2004.09.069
Funding
This work was supported by the grants from research project of SCUN (HZY18032).
Author information
Authors and Affiliations
Contributions
XTL wrote the manuscript.
Corresponding author
Ethics declarations
Not applicable.
Conflicts of interest
The authors state no conflict of interest.
Consent to Participate
Not applicable.
Informed consent
Not Applicable.
Consent for Publication
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, XT. Alzheimer’s disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels. Metab Brain Dis 37, 581–587 (2022). https://doi.org/10.1007/s11011-022-00921-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-022-00921-w